| Health / Medical Topics |
Hypoxia-activated Prodrug PR610
A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug PR610 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity. (NCI Thesaurus)
YOU MAY ALSO LIKE
Highly expressed in secretory tissues (liver and pancreas) by human HYOU1 Gene (HSP70 Family), hypoxia-induced 999-aa (precursor) 150 kD Hypoxia Up-Regulated 1…
Hypoxic stress, like DNA damage, induces p53 protein accumulation and p53-dependent apoptosis in oncogenically transformed cells. Unlike DNA damage, hypoxia does not…
A condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia…
A condition in which there is not enough oxygen in the blood.
Hypoxanthine-guanine phosphoribosyltransferase (218 aa, ~25 kDa) is encoded by the human HPRT1 gene. This protein plays a role in nucleoside metabolism. …
Cytoplasmic Hypoxanthine Phosphoribosyltransferases (Purine/Pyrimidine Phosphoribosyltransferase Family) catalyze the conversion of 5-phosphoribosyl-1-pyrophosphate and hypoxanthine, guanine, or 6-mercaptopurine to the corresponding 5'-mononucleotides and…
